1. Home
  2. BZAI vs CTNM Comparison

BZAI vs CTNM Comparison

Compare BZAI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BZAI
  • CTNM
  • Stock Information
  • Founded
  • BZAI 2010
  • CTNM 2009
  • Country
  • BZAI United States
  • CTNM United States
  • Employees
  • BZAI N/A
  • CTNM N/A
  • Industry
  • BZAI
  • CTNM
  • Sector
  • BZAI
  • CTNM
  • Exchange
  • BZAI Nasdaq
  • CTNM Nasdaq
  • Market Cap
  • BZAI 343.8M
  • CTNM 328.1M
  • IPO Year
  • BZAI N/A
  • CTNM 2024
  • Fundamental
  • Price
  • BZAI $2.56
  • CTNM $10.69
  • Analyst Decision
  • BZAI Strong Buy
  • CTNM Strong Buy
  • Analyst Count
  • BZAI 3
  • CTNM 5
  • Target Price
  • BZAI $8.33
  • CTNM $22.20
  • AVG Volume (30 Days)
  • BZAI 2.6M
  • CTNM 106.2K
  • Earning Date
  • BZAI 11-13-2025
  • CTNM 10-30-2025
  • Dividend Yield
  • BZAI N/A
  • CTNM N/A
  • EPS Growth
  • BZAI N/A
  • CTNM N/A
  • EPS
  • BZAI N/A
  • CTNM N/A
  • Revenue
  • BZAI $14,857,000.00
  • CTNM N/A
  • Revenue This Year
  • BZAI $2,295.50
  • CTNM N/A
  • Revenue Next Year
  • BZAI $269.04
  • CTNM N/A
  • P/E Ratio
  • BZAI N/A
  • CTNM N/A
  • Revenue Growth
  • BZAI 655.31
  • CTNM N/A
  • 52 Week Low
  • BZAI $1.70
  • CTNM $3.35
  • 52 Week High
  • BZAI $29.61
  • CTNM $19.21
  • Technical
  • Relative Strength Index (RSI)
  • BZAI 30.79
  • CTNM 46.61
  • Support Level
  • BZAI $3.10
  • CTNM $10.07
  • Resistance Level
  • BZAI $3.54
  • CTNM $11.75
  • Average True Range (ATR)
  • BZAI 0.32
  • CTNM 0.71
  • MACD
  • BZAI -0.17
  • CTNM -0.01
  • Stochastic Oscillator
  • BZAI 15.31
  • CTNM 37.50

About BZAI Blaize Holdings Inc. Common Stock

Blaize Holdings Inc provides customized, programmable processor architecture suite, artificial intelligence (AI)-enabled edge computing solutions. The company is a semiconductor and software technology company dedicated to revolutionizing the world of AI.

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: